Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hepion Pharmaceuticals ( (HEPA) ) has issued an update.
On March 16, 2026, Hepion Pharmaceuticals, Inc. disclosed that its CEO, Dr. Kaouthar Lbiati, had resigned from her position for personal reasons, marking a leadership change at the biopharmaceutical company. On April 13, 2026, the company entered into a separation agreement under which Dr. Lbiati will receive $225,000, a $30,625 pro-rated bonus payment, and six months of COBRA reimbursement, in exchange for a general release and confidentiality commitments.
The agreed financial package and release terms clarify the economic and legal framework of Dr. Lbiati’s departure and formally conclude her short tenure as CEO. This resolution provides stakeholders with more certainty around the leadership transition and the associated costs as Hepion moves forward under new executive management.
More about Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing pharmaceutical therapies, operating within the healthcare and life sciences industry, though the specific therapeutic areas are not described in the disclosure.
Average Trading Volume: 13,376
Technical Sentiment Signal: Strong Sell
Current Market Cap: $518.5K
See more insights into HEPA stock on TipRanks’ Stock Analysis page.